Supreme Court Allows Antitrust Challenge to Pay-for-Delay Drug Settlements Costing Consumers $3.5 Billion Annually

The Supreme Court ruled 5-3 in FTC v. Actavis that the Federal Trade Commission could bring antitrust challenges against “pay-for-delay” agreements where brand-name drug manufacturers pay generic competitors to delay bringing cheaper alternatives to market. The decision reversed lower …